Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity

Area of Science:

• Biochemistry
• Oncology
• Drug Delivery

Background:

• Cancer treatments require improved tumor selectivity to enhance efficacy and reduce toxicity.
• Proteases are key regulators in tumorigenesis and are often dysregulated in the tumor microenvironment.
• Conditional prodrug activation strategies leverage tumor-specific conditions for targeted drug delivery.

Purpose of the Study:

• To evaluate a novel affibody-based prodrug design for protease-dependent activation.
• To demonstrate selective tumor targeting and shielded uptake in healthy tissues in vivo.
• To assess the potential for widening the therapeutic index of cytotoxic therapeutics.

Main Methods:

• Development of an affibody-based prodrug incorporating a protease substrate sequence.
• In vitro testing of prodrug activation via proteolytic cleavage.
• In vivo evaluation of prodrug targeting and uptake in tumor-bearing mice.

Main Results:

• The novel prodrug design demonstrated protease-dependent activation.
• Selective targeting of tumor sites with reduced uptake in healthy tissues was observed in vivo.
• The approach shows potential for enhanced drug delivery and reduced systemic toxicity.

Conclusions:

• Affibody-based prodrugs with protease-cleavable linkers offer a promising strategy for tumor-selective drug delivery.
• This approach can improve the safety and efficacy of cancer therapeutics, including epidermal growth factor receptor (EGFR)-targeted drugs.
• Conditional activation by tumor-associated proteases enhances therapeutic selectivity and widens the therapeutic index.